公开(公告)号：US12221417B2

公开(公告)日：2025-02-11

申请号：US18520156

申请日：2023-11-27

Applicant: Cytokinetics, Inc.

Inventor： Sheng Cui ,  Henry Morrison ,  Karthik Nagapudi ,  Shawn D. Walker ,  Charles Bernard ,  Karl Bennett Hansen ,  Neil Fred Langille ,  Alan Martin Allgeier ,  Steven Mennen ,  Jacqueline C. S. Woo

IPC: A61K31/496 ,  A61K9/20 ,  A61K31/444 ,  A61K47/38 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  C07D213/75

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：USRE50267E1

公开(公告)日：2025-01-14

申请号：US17747917

申请日：2022-05-18

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Thuy-Anh Tran ,  Weichao Chen ,  Bryan A. Kramer ,  Abu J. M. Sadeque ,  Anna Shifrina ,  Young-Jun Shin ,  Pureza Vallar ,  Ning Zou

IPC: A61K31/195 ,  A61K31/27 ,  A61K31/325 ,  A61K31/381 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4965 ,  C07C271/12 ,  C07C271/28 ,  C07C275/24 ,  C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C309/15 ,  C07D213/75 ,  C07D241/20 ,  C07D277/48 ,  C07D333/36

Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: Pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis, atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

公开(公告)号：US20240376055A1

公开(公告)日：2024-11-14

申请号：US18572114

申请日：2022-06-30

Applicant: Zedira GmbH

Inventor： Ralf Pasternack ,  Christian Büchold ,  Martin Hils ,  Martin Stieler ,  Uwe Gerlach

IPC: C07D213/75 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/08 ,  C07D513/04

Abstract: The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use for the prophylaxis and treatment of diseases associated with transglutaminases, in particular transglutaminase 2.

公开(公告)号：US20240358019A1

公开(公告)日：2024-10-31

申请号：US18686170

申请日：2022-08-30

Applicant: BASF SE

Inventor： Marc Heinrich ,  Markus Kordes ,  Tobias Seiser ,  Gunther Zimmermann ,  Trevor William Newton ,  Gerd Kraemer

IPC: A01N43/40 ,  A01N43/10 ,  A01N43/36 ,  A01N43/54 ,  A01N43/58 ,  A01N43/78 ,  A01N43/80 ,  A01P13/00 ,  C07D207/34 ,  C07D213/75 ,  C07D237/20 ,  C07D239/42 ,  C07D261/14 ,  C07D277/56 ,  C07D333/38

CPC classification number: A01N43/40 ,  A01N43/10 ,  A01N43/36 ,  A01N43/54 ,  A01N43/58 ,  A01N43/78 ,  A01N43/80 ,  A01P13/00 ,  C07D207/34 ,  C07D213/75 ,  C07D237/20 ,  C07D239/42 ,  C07D261/14 ,  C07D277/56 ,  C07D333/38

Abstract: The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of the said malonamide compounds or the corresponding compositions for controlling unwanted vegetation. Furthermore, the invention relates to methods of applying said malonamide compounds or the corresponding compositions.

公开(公告)号：US20240336563A1

公开(公告)日：2024-10-10

申请号：US18287634

申请日：2022-04-26

Applicant: The Regents of the University of California

Inventor： Kevan M. Shokat ,  Qi Hu ,  Shizhong Dai

IPC: C07C323/44 ,  A61K31/165 ,  A61K31/17 ,  A61K31/381 ,  A61K31/41 ,  A61K31/42 ,  A61K31/433 ,  A61K31/505 ,  A61K31/53 ,  A61K47/64 ,  A61P35/00 ,  C07D213/75 ,  C07D239/34 ,  C07D257/06 ,  C07D261/14 ,  C07D285/135 ,  C07D333/70

CPC classification number: C07C323/44 ,  A61K31/165 ,  A61K31/17 ,  A61K31/381 ,  A61K31/41 ,  A61K31/42 ,  A61K31/433 ,  A61K31/505 ,  A61K31/53 ,  A61K47/64 ,  A61P35/00 ,  C07D213/75 ,  C07D239/34 ,  C07D257/06 ,  C07D261/14 ,  C07D285/135 ,  C07D333/70

Abstract: Disclosed herein, inter alia, are G-alpha-s Inhibitors and uses thereof.

公开(公告)号：US20240317687A1

公开(公告)日：2024-09-26

申请号：US18421849

申请日：2024-01-24

Applicant: Cytokinetics, Inc.

Inventor： Sheng CUI ,  Henry MORRISON ,  Karthik NAGAPUDI ,  Shawn D. WALKER ,  Charles BERNARD ,  Karl Bennett HANSEN ,  Neil Fred LANGILLE ,  Alan Martin ALLGEIER ,  Steven M. MENNEN ,  Jacqueline C.S. WOO ,  Bradley Paul MORGAN ,  Alex MUCI (Deceased)

IPC: C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

CPC classification number: C07D213/75 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/496 ,  A61K47/38

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US12012418B2

公开(公告)日：2024-06-18

申请号：US17859505

申请日：2022-07-07

Applicant: Nogra Pharma Limited

Inventor： Francesca Viti ,  Salvatore Bellinvia ,  Salvatore Demartis

IPC: C07D495/14 ,  C07C233/29 ,  C07C233/73 ,  C07C235/38 ,  C07C235/46 ,  C07D209/08 ,  C07D209/14 ,  C07D209/86 ,  C07D209/94 ,  C07D213/75 ,  C07D235/30 ,  C07D277/64 ,  C07D277/82 ,  C07D333/36 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

CPC classification number: C07D495/14 ,  C07C233/29 ,  C07C233/73 ,  C07C235/38 ,  C07C235/46 ,  C07D209/08 ,  C07D209/14 ,  C07D209/86 ,  C07D209/94 ,  C07D213/75 ,  C07D235/30 ,  C07D277/64 ,  C07D277/82 ,  C07D333/36 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

Abstract: The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-γ in a subject.

公开(公告)号：US20240174605A1

公开(公告)日：2024-05-30

申请号：US18279985

申请日：2022-03-01

Applicant: RESEARCH TRIANGLE INSTITUTE

Inventor： Yanan ZHANG ,  Dehui ZHANG

IPC: C07C311/37 ,  A61K31/167 ,  A61K31/18 ,  A61K31/381 ,  A61K31/40 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/496 ,  A61P25/28 ,  C07C237/42 ,  C07D213/40 ,  C07D213/75 ,  C07D213/76 ,  C07D213/81 ,  C07D213/82 ,  C07D277/56 ,  C07D295/16 ,  C07D333/38 ,  C07D401/12 ,  C07D417/12

CPC classification number: C07C311/37 ,  A61K31/167 ,  A61K31/18 ,  A61K31/381 ,  A61K31/40 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/496 ,  A61P25/28 ,  C07C237/42 ,  C07D213/40 ,  C07D213/75 ,  C07D213/76 ,  C07D213/81 ,  C07D213/82 ,  C07D277/56 ,  C07D295/16 ,  C07D333/38 ,  C07D401/12 ,  C07D417/12 ,  C07C2601/02

Abstract: The present disclosure provides novel arylsulfonamide compounds as embodiments of the present disclosure. The compounds are believed to be orexin receptor agonists, useful for the treatment of diseases and conditions caused by reduced activity of orexin.

公开(公告)号：US11958809B2

公开(公告)日：2024-04-16

申请号：US17448833

申请日：2021-09-24

Applicant: Cytokinetics, Inc.

Inventor： Sheng Cui ,  Henry Morrison ,  Karthik Nagapudi ,  Shawn D. Walker ,  Charles Bernard ,  Karl Bennett Hansen ,  Neil Fred Langille ,  Alan Martin Allgeier ,  Steven M. Mennen ,  Jacqueline C. S. Woo ,  Bradley Paul Morgan ,  Alex Muci

IPC: C07D213/75 ,  A61K9/20 ,  A61K31/444 ,  A61K31/496 ,  A61K47/38 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06

CPC classification number: C07D213/75 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/496 ,  A61K47/38

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20240116981A1

公开(公告)日：2024-04-11

申请号：US18321803

申请日：2023-05-23

Applicant: BELYNTIC GMBH

Inventor： Robert ZITTERBART ,  Oliver REIMANN

IPC: C07K1/22 ,  C07C247/18 ,  C07D213/75 ,  C07D295/185

CPC classification number: C07K1/22 ,  C07C247/18 ,  C07D213/75 ,  C07D295/185

Abstract: The present invention relates to linker molecules of formula (1), X-Tb-Va-U-Y-Z (1) and a method for purifying peptides using said linker molecules. The linker molecule can be coupled to a purification resin via the moiety X and to a peptide via the moiety Y under the release of the leaving group Z. T is an optional spacer moiety and V is an optional electron withdrawing moiety. U is an aryl or 5- or 6-membered heteroaryl moiety bound to at least one electron withdrawing moiety V, W or E. The linker is stable under acidic conditions and releases the peptide upon addition of a reducing agent.